Patent · US Active

Terminally Modified RNA

US10925935B2 · kind B2 · utility

17Cited by

4References

37Claims

0Family size

Assignee

ModernaTX, Inc. · US

Inventors

Tirtha Chakraborty · Medford, US
Stephane Bancel · Cambridge, US
Stephen Hoge · Brookline, US
Atanu Roy · Stoneham, US
Antonin de Fougerolles · Waterloo, BE
Noubar B. Afeyan · Lexington, US

Key dates

Filing date	Oct 5, 2018
Grant date	Feb 23, 2021
Priority date	—
Expiry date	Oct 5, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/67
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.